Effect of Food on BIA 5-1058

Inclusion Criteria: 1. Able and willing to give written informed consent and to comply with the study restrictions; 2. Male or female subjects aged 18 to 45 years, inclusive; 3. Body mass index (BMI) between 18 and 30 kg/m2, inclusive; 4. Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead electrocardiogram (ECG); 5. Negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus antibodies (HCV Ab) and anti-human immunodeficiency virus antibodies (HIV-1 and HIV-2 Ab) at screening; 6. Clinical laboratory test results clinically acceptable at screening and admission to each treatment period; 7. Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period; 8. Non-smokers or ex-smokers for at least 3 months. If female: 9. No childbearing potential by reason of surgery or at least 1 year post menopause (i.e., 12 months post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing; 10. If of childbearing potential, she was using an effective non-hormonal method of contraception \[intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical or vault caps) with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he is the sole partner of that subject\] for all the duration of the study; 11. Negative serum pregnancy test at screening and negative urine pregnancy test on admission of each treatment period (women of childbearing potential only). If male: 12. Using an effective method of contraception with a pregnant partner or partner of childbearing potential (condom or occlusive cap \[diaphragm or cervical or vault caps\] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomy) throughout the study; 13. Refraining from donating sperm throughout the study. Exclusion Criteria: 1. Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders; 2. Clinically relevant surgical history; 3. History of relevant atopy or drug hypersensitivity; 4. History of alcoholism or drug abuse; 5. Consumption of more than 14 units of alcohol a week \[1 glass (25 cL) of beer with 3° of alcohol = 7.5 g, or 1 glass (25 cL) of beer with 6° of alcohol = 15 g, or 1 glass (12.5 cL) of wine with 10° of alcohol = 12 g, or 1 glass (4cL) of aperitif with 42° of alcohol = 17 g\]; 6. Significant infection or known inflammatory process at screening or admission to each treatment period; 7. Display of acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period; 8. Use of medicines within 2 weeks of admission to the first period that may could affect the safety or other study assessments, in the Investigator's opinion; 9. Previous administration of BIA 5-1058; 10. Use of any investigational drug or participation in any clinical trial within 90 days prior to screening; 11. Participation in more than 2 clinical trials within the 12 months prior to screening; 12. Donation or reception of any blood or blood products within the 3 months prior to screening; 13. Vegetarians, vegans or had any other medical dietary restrictions; 14. Not able to communicate reliably with the Investigator; 15. Unlikely to co-operate with the requirements of the study. If female: 16. Pregnant or breastfeeding; 17. Not using an accepted effective contraceptive method or was using oral contraceptives. If male: 18. Not using an accepted effective method of contraception; 19. Refusing to refrain from donating sperm throughout the study.